Healthcare
Nika Pharmaceuticals Inc.(NIKA)
Live Price
Offline$0.5098
+0.00% today
1Y Change
-35.65%
Window
Jun 25, 2025 → Jun 24, 2026
- Market Cap
- $420.00M
- Revenue Growth
- 0.0%
- EPS Growth
- 0.0%
- Dividend Yield
- 0.0%
Coverage: 252 bars · Jun 25, 2025 → Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nika Pharmaceuticals Inc. (NIKA) is a Healthcare stock with a market cap of $420.00M and listed on OTC. The stock last traded around $0.51 and down 35.7% across the available one-year price window (Jun 25, 2025 → Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow +42.7% with operating margin 0.0% and ROIC 25.7%. Stock Foundry combines NIKA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is 0.0%, while operating margin sits near 0.0%.
Benchmark Edge
NIKA vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NIKA
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NIKA Max Drawdown
-79.11%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NIKA and SPY.
Company Overview
Nika Pharmaceuticals Inc.
Other OTC
Nika Pharmaceuticals, Inc., a pharmaceutical company, develops drugs for the treatment of HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, diabetes, and various other diseases. It offers dietary supplements and antiviral drugs, as well as thymus nuclear glycoprotein for the treatment of HIV. The company was formerly known as Centennial Growth Equities Inc. and changed its name to Nika Pharmaceuticals, Inc. in May 2022. Nika Pharmaceuticals, Inc. was incorporated in 2000 and is based in Henderson, Nevada.
- Leadership
- Dimitar Slavchev Savov
- IPO Date
- Mar 14, 2024
- Street Address
- 2269 Merrimack Valley Avenue
- Mailing
- Henderson, NV, 89044
- Region
- Henderson, NV, US
- Reporting Currency
- USD
- Investor Line
- 702 326 3615
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- 0.0%
- EPS
- 0.0%
- Free Cash Flow
- +42.7%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 29.2%
- ROIC
- 25.7%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.